Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices

(2019) Scott D. Ramsey et al.   JAMA Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2018) J B A G Haanen et al.   ANNALS OF ONCOLOGY

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

(2018) Norah A. Terrault et al.   HEPATOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

(2018) Martin Tio et al.   EUROPEAN JOURNAL OF CANCER

Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions

(2017) Rohit Loomba et al.   GASTROENTEROLOGY

Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis

(2017) Hyosun Cho et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A

(2016) Hyosun Cho et al.   Gut and Liver

Hepatic Immune Regulation and Its Involvement in Viral Hepatitis Infection

(2014) Percy A. Knolle et al.   GASTROENTEROLOGY

Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy

(2014) He Huang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection

(2013) David Gardiner et al.   PLoS One

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

(2009) Daniel J. Tenney et al.   HEPATOLOGY

PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV

(2009) Debora Franceschini et al.   JOURNAL OF CLINICAL INVESTIGATION

Clearance of hepatitis C in chimpanzees is associated with intrahepatic T-cell perforin expression during the late acute phase

(2009) H. Watanabe et al.   JOURNAL OF VIRAL HEPATITIS

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab

(2008) Winnie Yeo et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatitis B Virus Infection

(2008) Jules L. Dienstag   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients

(2007) Guoping Peng et al.   MOLECULAR IMMUNOLOGY